PACB Files 8-K on Financial Condition, NASDAQ Listing Confirmed

TL;DR

**PACB filed an 8-K, confirming its NASDAQ listing and regulatory compliance.**

AI Summary

Pacific Biosciences of California, Inc. (PACB) filed an 8-K on January 8, 2024, to report on its financial condition and other events. This filing indicates that the company's common stock, with a par value of $0.001 per share, is registered on The NASDAQ Stock Market LLC under the trading symbol PACB. This matters to investors because it confirms the company's continued compliance with SEC regulations and its listing on a major stock exchange, providing transparency and liquidity for shareholders.

Why It Matters

This filing confirms Pacific Biosciences' ongoing compliance with SEC regulations and its listing on NASDAQ, which is crucial for investor confidence and stock liquidity.

Risk Assessment

Risk Level: low — This 8-K filing is routine and primarily confirms existing information, posing minimal new risk to investors.

Analyst Insight

Investors should note this routine filing confirms PACB's continued regulatory compliance and NASDAQ listing, which are foundational for trading. No immediate action is suggested by this specific filing, but it serves as a baseline for future financial disclosures.

Key Numbers

• $0.001 — Par value per share (The par value of Pacific Biosciences' common stock.)
• 001-34899 — Commission File Number (The SEC file number for Pacific Biosciences.)

Key Players & Entities

• PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — the registrant filing the 8-K
• The NASDAQ Stock Market LLC (company) — the exchange where PACB common stock is registered
• $0.001 (dollar_amount) — par value per share of common stock
• January 8, 2024 (date) — date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market

Filing Documents

• pacb-20240108.htm (8-K) — 27KB
• exhibit991-12312023xearnin.htm (EX-99.1) — 16KB
• 0001299130-24-000005.txt ( ) — 172KB
• pacb-20240108.xsd (EX-101.SCH) — 2KB
• pacb-20240108_lab.xml (EX-101.LAB) — 23KB
• pacb-20240108_pre.xml (EX-101.PRE) — 12KB
• pacb-20240108_htm.xml (XML) — 3KB

02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On January 8, 2024, Pacific Biosciences of California, Inc. (the "Company") issued a press release providing a business update and announcing certain unaudited preliminary financial results as of and for the quarter and year ended December 31, 2023 (the "Press Release"). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. OTHER EVENTS

ITEM 8.01. OTHER EVENTS. The information set forth in the Press Release, solely to the extent such information references the Company's expectations for preliminary revenue estimates for the quarter and year ended December 31, 2023 and preliminary cash, cash equivalents and investments balance as of December 31, 2023, together with the paragraph set forth under the heading "Forward-looking statements", is incorporated by reference into Item 8.01 of this Current Report on Form 8-K. The portions of the Press Release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the Press Release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Because the Company's financial statements as of and for the quarter and year ended December 31, 2023 have not yet been finalized or audited and remain subject to change, the Company's final results for such periods may differ materially from the unaudited preliminary financial information included in the Press Release. Accordingly, you should not place undue reliance on the unaudited preliminary financial information included in the Press Release.

01. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release issued by Pacific Biosciences of California, Inc. dated January 8 , 202 4 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: January 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR